141 related articles for article (PubMed ID: 2892253)
1. Safety of nizatidine in clinical trials conducted in the USA and Europe.
Cloud ML
Scand J Gastroenterol Suppl; 1987; 136():29-36. PubMed ID: 2892253
[TBL] [Abstract][Full Text] [Related]
2. Nizatidine versus ranitidine in the treatment of peptic ulcer disease: report on the Dutch investigation as part of a European multicentre trial.
Kuipers EJ; Hazenberg HJ; Quik RF; Hazenberg BP; de Zwart PA
Neth J Med; 1990 Aug; 37(1-2):58-62. PubMed ID: 1977089
[TBL] [Abstract][Full Text] [Related]
3. 300 mg nizatidine at night versus 300 mg ranitidine at night in patients with duodenal ulcer. A multicentre trial in Europe.
Simon B; Cremer M; Dammann HG; Hentschel E; Keohane PP; Mulder H; Müller P; Sarles H
Scand J Gastroenterol Suppl; 1987; 136():61-70. PubMed ID: 2892257
[TBL] [Abstract][Full Text] [Related]
4. Nizatidine in the short-term treatment of duodenal ulcer--an Italian Multicenter Study.
Bovero E; Poletti M; Boero A; Mura BC; Camarri E; Corradini P; Corsini G; Federici G; Curzio M; Gianquinto G
Hepatogastroenterology; 1987 Dec; 34(6):269-71. PubMed ID: 2892768
[TBL] [Abstract][Full Text] [Related]
5. Nizatidine and ranitidine in the short-term treatment of duodenal ulcer: a cooperative double-blind study of once-daily bedtime administration.
Pace F; Colombo E; Ferrara A; Prada A; Rocca F; Bianchi Porro G
Am J Gastroenterol; 1988 Jun; 83(6):643-5. PubMed ID: 2897784
[TBL] [Abstract][Full Text] [Related]
6. Nizatidine versus ranitidine in the prevention of duodenal ulcer relapse. Six-month interim results of a European multicentre study.
Hentschel E; Schütze K; Reichel W; Kerstan E; Kratochvil P; Brandstätter G; Judmaier G; Keohane PP
Scand J Gastroenterol Suppl; 1987; 136():84-8. PubMed ID: 2892260
[TBL] [Abstract][Full Text] [Related]
7. Nizatidine as maintenance therapy of duodenal ulcer disease in remission.
Cerulli MA; Cloud ML; Offen WW; Chernish SM; Matsumoto C
Scand J Gastroenterol Suppl; 1987; 136():79-83. PubMed ID: 2892259
[TBL] [Abstract][Full Text] [Related]
8. Nizatidine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease.
Price AH; Brogden RN
Drugs; 1988 Nov; 36(5):521-39. PubMed ID: 2905640
[TBL] [Abstract][Full Text] [Related]
9. Nizatidine: a new histamine receptor blocker in the treatment of active duodenal ulcers.
Levendoglu H; Mehta B; Wait C; Reddy G; Hatcher C
Am J Gastroenterol; 1986 Dec; 81(12):1167-70. PubMed ID: 2878607
[TBL] [Abstract][Full Text] [Related]
10. Clinical review of histamine2 receptor antagonists.
Lipsy RJ; Fennerty B; Fagan TC
Arch Intern Med; 1990 Apr; 150(4):745-51. PubMed ID: 1970232
[TBL] [Abstract][Full Text] [Related]
11. [Nizatidine versus ranitidine in the treatment of acute duodenal ulcer. Comparison of 300 mg nizatidine and 300 mg ranitidine in a single evening dose].
Arnold R; Beckenbach P; Bock H; Bormann R; Daake H; Dammann HG; Du Bosque G; Fürer M; Geiter B; Hebbeln H
Fortschr Med; 1989 Jul; 107(21):467-70. PubMed ID: 2570012
[TBL] [Abstract][Full Text] [Related]
12. Nizatidine (AXID).
Med Lett Drugs Ther; 1988 Aug; 30(772):77-8. PubMed ID: 2899835
[No Abstract] [Full Text] [Related]
13. The effect of an oral morning dose of nizatidine and ranitidine on gastric acid secretion in duodenal ulcer patients.
Lazzaroni M; Bianchi Porro G
Hepatogastroenterology; 1989 Dec; 36(6):490-3. PubMed ID: 2575571
[TBL] [Abstract][Full Text] [Related]
14. Nizatidine versus ranitidine in gastric ulcer disease. A European multicentre trial.
Naccaratto R; Cremer M; Dammann HG; Keohane PP; Mulder H; Sarles H; Simon B
Scand J Gastroenterol Suppl; 1987; 136():71-8. PubMed ID: 2892258
[TBL] [Abstract][Full Text] [Related]
15. Healing and recurrence of active duodenal ulcer with nizatidine.
Cloud ML; Offen WW; Matsumoto C; Chernish SM
Clin Pharmacol Ther; 1989 Sep; 46(3):310-6. PubMed ID: 2570656
[TBL] [Abstract][Full Text] [Related]
16. [Nizatidine].
Romero M; Franzosi MG
Medicina (Firenze); 1989; 9(1):93-6. PubMed ID: 2567957
[TBL] [Abstract][Full Text] [Related]
17. Clinical importance of the new H2-antagonists.
Walt RP
Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():97-9. PubMed ID: 2566730
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 150 mg nizatidine BID or 300 mg at bedtime, and 150 mg ranitidine BID in the treatment of gastric ulcer--an 8-week randomized, double-blind multicentre study.
Di Mario F; Battaglia G; Naccarato R; D'Angelo A; Saggioro A; Da Broi GL; Vezzadini P; Bianchi Porro G
Hepatogastroenterology; 1990 Dec; 37 Suppl 2():62-5. PubMed ID: 1982108
[TBL] [Abstract][Full Text] [Related]
19. Nizatidine in peptic ulcer disease. Proceeedings of the First International Symposium on Nizatidine. Vienna, 11 and 12 October 1986.
Scand J Gastroenterol Suppl; 1987; 136():1-88. PubMed ID: 2892250
[No Abstract] [Full Text] [Related]
20. [Treatment of acute stomach ulcer with H2 receptor antagonists. A direct therapy comparison with 300 mg nizatidine nightly and 2 times 150 mg nizatidine with twice daily 150 mg ranitidine].
Arnold R; Beckenbach P; Bock H; Bormann R; Brunner G; Daake H; Dammann HG; Dietrich K; Fuerer M; Geiter B
Fortschr Med; 1989 Jun; 107(17):390-4. PubMed ID: 2568327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
